Rational Pharmacotherapy in Cardiology

Advanced search

Modern Anticoagulant Therapy for Atrial Fibrillation: Patient Adherence in Clinical Practice


Aim. To assess the adherence of doctors and patients to anticoagulant therapy for atrial fibrillation (AF).

Materials and methods. An observational prospective study included 99 patients with AF at high risk of thromboembolic complications in Ryazan and Omsk. To study adherence, a questionnaire for quantitative assessment of treatment adherence ("QAA-25") was used. The questionnaire allows you to assess adherence by three main parameters separately: adherence to drug therapy, lifestyle modification and medical support. For the purposes of the study, adherence rates of less than 75% were regarded as insufficient, 75%. % or more as sufficient. To assess food preferences and determine the risk of changes in the activity of warfarin, a questionnaire of food preferences was used. The questionnaire allows you to assess the risk of alimentary increase (≥30 points) and decrease (≥60 points) of warfarin activity, as well as the overall risk of alimentary change (≥90 points) of warfarin activity in each patient, taking into account the volume and frequency of consumption of products that affect the activity of warfarin.

Results. After the first visit, 99% of respondents received anticoagulant treatment. Rivaroxaban was the leader in prescribability among anticoagulants (36.7%). About a third of respondents were prescribed apixaban by a doctor (30.6%) and dabigatran  (17.3%)  and  warfarin  (19.4%)  were prescribed almost twice as rarely as rivaroxaban. Respondents with the highest rates of adherence to drug therapy, lifestyle modification and medical support are AF patients taking apixaban. The respondents who were prescribed rivaroxaban had the lowest level of adherence to drug therapy and lifestyle modification. And the lowest level of commitment to medical support is among respondents who have been prescribed warfarin. The number of people with a sufficient level of commitment did not reach half. Only 43.9% were ready to take prescribed medications and slightly more than a third (34.7%) agreed to come to appointments for a long time. But, despite the importance of lifestyle modification in patients with AF, only 16.3% of respondents said they were ready to give up bad habits, lose weight and lead a more active lifestyle. The proportion of people with sufficient adherence to drug therapy was the smallest in the group taking rivaroxaban (25.7%). The least number of respondents with sufficient commitment to medical support in the group taking dabigatran (25%). Only one in ten patients (11.1%) taking warfarin had a sufficient level of commitment to lifestyle modification. 15% of the study participants had an increased risk of alimentary changes in the activity of warfarin.

Conclusion. Assessment of adherence to anticoagulant therapy by doctors in two regional centers (Omsk and Ryazan) showed high prescribability of preventive antithrombotic therapy, which corresponds to modern therapeutic approaches. At the same time, patients demonstrated rather low levels of adherence to drug therapy, lifestyle modification, and medical support.

About the Authors

Yu. P. Skirdenko
Omsk State Medical University; National Medical Research Center for Therapy and Preventive Medicine
Russian Federation

Yulia P. Skirdenko.

Omsk; Moscow.

eLibrary SPIN 6719-2581

N. A. Nikolaev
Omsk State Medical University
Russian Federation

Nikolai A. Nikolaev.


eLibrary  SPIN  8807-9519

K. G. Pereverzeva
Ryazan State Medical University
Russian Federation

Kristina G. Pereverzeva.


eLibrary SPIN 4995-1465

A. Yu. Timakova
Omsk State Medical University
Russian Federation

Arina Yu. Timakova.


eLibrary SPIN 6597-3179

A. S. Galus
Ryazan State Medical University
Russian Federation

Anna S. Galus.


S. S. Yakushin
Ryazan State Medical University
Russian Federation

Sergey S. Yakushin.


eLibrary SPIN 7726-7198


1. Roselli C, Rienstra M, Ellinor PT. Genetics of Atrial Fibrillation in 2020: GWAS, Genome Sequencing, Polygenic Risk, and beyond. Circ Res. 2020;127(1):21-33. DOI:10.1161/CIRCRESAHA.120.316575.

2. Nesheiwat Z, Goyal A, Jagtap M. Atrial Fibrillation. 2020 Nov 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. PMID:30252328 [cited 2021 Jun 15]. Available from:

3. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217-21. DOI:10.1177/1747493019897870.

4. Kornej EJ, Benjamin EJ, Magnani JW. Atrial fibrillation: Global burdens and global opportunities. Heart. 2021;107(7):516-8. DOI:10.1136/heartjnl-2020-318480.

5. Storz MA, Helle P. Atrial fibrillation risk factor management with a plant-based diet: A review. J Arrhythm. 2019;35(6):781-8. DOI:10.1002/joa3.12254.

6. Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of Atrial Fibrillation in the 21stCentury: Novel Methods and New Insights. Circ Res. 2020;127(1):4-20. DOI:10.1161/CIRCRESAHA.120.316340.

7. Ardashev AV, Belenkov YN, Matsiukevich MC, Snezhitskiy VA. Atrial fibrillation and mortality: Prognostic factors and direction of prevention. Kardiologiia. 2021;61(2):91-8 (In Russ.) DOI:10.18087/CARDIO.2021.2.N1348.

8. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.

9. Atrial fibrillation and flutter. Clinical guidelines 2020 [cited 2021 Jun 15]. Available from: (In Russ.)

10. Korennova OY, Maltsev SN. Atrial fibrillation in real clinical practice: lessons from a regionalregister. Difficult Patient. 2015;4(13):8-11 (In Russ.)

11. Zvereva PI, Fedorin MM, Skirdenko YuP, Nikolaev NA. Antithrombotic therapy for non-valvular atrial fibrillation: problems of adequate choice. Medical Sciences. 2018;(2):9-14 (In Russ.)

12. Linchak RM, Kompaniets OG, Nedbaikin AM, et al. What physicians think and know aboutantithrombotic therapy in atrial fibrillation. Kardiologiia. 2014;54(10):32-8 (In Russ.) DOI:10.18565/cardio.2014.10.32-38.

13. Hurtado-Navarro I, García-Sempere A, Rodríguez-Bernal C, et al. Estimating Adherence Based on Prescription or Dispensation Information: Impact on Thresholds and Outcomes. A Real-World Study With Atrial Fibrillation Patients Treated With Oral Anticoagulants in Spain. Front Pharmacol. 2018;9:1353. DOI:10.3389/fphar.2018.01353.

14. Kim D, Yang PS, Jang E, et al. The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients. Europace. 2020;22(4):547-57. DOI:10.1093/europace/euz273.

15. Borne RT, O’Donnell C, Turakhia MP, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovasc Disord. 2017;17(1):236. DOI:10.1186/s12872-01706716.

16. Nikolaev NA, Skirdenko YuP. Russian universal questionnaire for quantitative assessment ofadherence to treatment (QAA-25). Clinical Pharmacology and Therapy. 2018;27(1):74-8 (In Russ.)

17. Skirdenko YP, Nikolaev NA. Assessment of individual risk of food interactions while taking warfarin. Ter Arhiv. 2021;93(2):187-92 (In Russ.) DOI:10.26442/00403660.2021.02.200611.

18. Baranova EI, Soboleva AV, Aznauryan RS, et al. Adequacy of antithrombotic therapy for non-valvular atrial fibrillation in real clinical practice. Atherothrombosis. 2015;(1):16-23 (In Russ.)

19. Novikova TN, Ashurov AB, Kiseleva MV, et al. Stroke prevention in patients with atrial fibrillation in real clinical practice, emphasis on efficacy and safety of anticoagulant therapy. Kardiologiia. 2020;60(4):54-61 (In Russ.) DOI:10.18087/cardio.2020.4.n1023.

20. Hernandez I, He M, Chen N, et al. Trajectories of Oral Anticoagulation Adherence Among Medicare Beneficiaries Newly Diagnosed With Atrial Fibrillation. J Am Heart Assoc. 2019;8(12):27-9. DOI:10.1161/JAHA.118.011427.

21. Bunova SS, Zhernakova NI, Skirdenko YP, Nikolaev NA. Adherence to therapy, lifestyle modification and medical support of cardiovascular patients. Cardiovasc Ther Prev. 2020;19(6):38-42 (In Russ.) DOI:10.15829/1728-8800-2020-2665.

22. Skirdenko YP, Nikolaev NA. Algorithm for the choice of anticoagulant for patients with atrialfibrillation. Rational Pharmacotherapy in Cardiology. 2020;16(2):199-205 (In Russ.) DOI:10.20996/1819-6446-2020-04-1.


For citations:

Skirdenko Yu.P., Nikolaev N.A., Pereverzeva K.G., Timakova A.Yu., Galus A.S., Yakushin S.S. Modern Anticoagulant Therapy for Atrial Fibrillation: Patient Adherence in Clinical Practice. Rational Pharmacotherapy in Cardiology. 2022;18(1):49-55. (In Russ.)

Views: 421

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)